<DOC>
	<DOC>NCT02781571</DOC>
	<brief_summary>This study will evaluate the efficacy, safety, and tolerability of sofosbuvir /velpatasvir (SOF/VEL) fixed-dose combination (FDC) in participants with chronic hepatitis C virus (HCV) who have received a liver transplant.</brief_summary>
	<brief_title>Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key History of chronic HCV prior to liver transplant with HCV reoccurrence posttransplant HCV genotype 1, 2, 3, 4, 5, 6, or indeterminate Individuals â‰¥ 3 months postliver transplant with chronic HCV reoccurrence Male and nonpregnant/ nonlactating female individuals without cirrhosis or with compensated cirrhosis Metavir stage 3 or 4 fibrosis/cirrhosis or corresponding fibrosis Key History of clinically significant illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol, Coinfection with HIV or hepatitis B virus Known hypersensitivity to study medication, Use of any prohibited concomitant medications as within with window before the Day 1 visit. NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>